Agios Pharmaceuticals (AGIO) Projected to Announce Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is projected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($1.6548) per share and revenue of $26.3950 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. The business’s revenue was up 137.7% compared to the same quarter last year. On average, analysts expect Agios Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

AGIO opened at $36.97 on Tuesday. The stock has a fifty day moving average of $34.07 and a 200-day moving average of $30.76. The company has a market capitalization of $2.20 billion, a P/E ratio of -5.10 and a beta of 0.54. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $25,000. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $49,000. Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals during the third quarter worth $79,000. Finally, Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the first quarter worth $133,000.

Analyst Ratings Changes

A number of analysts have issued reports on AGIO shares. HC Wainwright cut their price objective on shares of Agios Pharmaceuticals from $54.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. JPMorgan Chase & Co. lowered their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. The Goldman Sachs Group lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada boosted their price target on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $40.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.